Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
17 08 2021
Historique:
received: 01 03 2021
revised: 25 05 2021
accepted: 28 07 2021
entrez: 18 8 2021
pubmed: 19 8 2021
medline: 10 2 2022
Statut: ppublish

Résumé

Elicitation of broadly neutralizing antibodies (bnAbs) by an HIV vaccine will involve priming the immune system to activate antibody precursors, followed by boosting immunizations to select for antibodies with functional features required for neutralization breadth. The higher the number of acquired mutations necessary for function, the more convoluted are the antibody developmental pathways. HIV bnAbs acquire a large number of somatic mutations, but not all mutations are functionally important. In this study, we identify a minimal subset of mutations sufficient for the function of the naturally occurring V3-glycan bnAb DH270.6. Using antibody library screening, candidate envelope immunogens that interact with DH270.6-like antibodies containing this set of key mutations are identified and selected in vitro. Our results demonstrate that less complex B cell evolutionary pathways than those naturally observed exist for the induction of HIV bnAbs by vaccination, and they establish rational approaches to identify boosting candidate immunogens.

Identifiants

pubmed: 34407396
pii: S2211-1247(21)00995-5
doi: 10.1016/j.celrep.2021.109561
pmc: PMC8493474
mid: NIHMS1734084
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
env Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109561

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI131251
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144371
Pays : United States

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Cell. 2016 Sep 8;166(6):1471-1484.e18
pubmed: 27610571
Cell. 2015 Jun 18;161(7):1505-15
pubmed: 26091035
Cell. 2016 Sep 8;166(6):1459-1470.e11
pubmed: 27610570
Sci Transl Med. 2019 Oct 30;11(516):
pubmed: 31666399
Annu Rev Biochem. 2008;77:363-82
pubmed: 18410248
Front Immunol. 2013 Nov 15;4:358
pubmed: 24298272
Immunity. 2020 Oct 13;53(4):840-851.e6
pubmed: 33053332
Genome Res. 2004 Jun;14(6):1188-90
pubmed: 15173120
Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):8614-8619
pubmed: 28747530
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298421
PLoS Pathog. 2019 Sep 17;15(9):e1008026
pubmed: 31527908
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100831
Methods Enzymol. 2011;487:545-74
pubmed: 21187238
Cell. 2013 Mar 28;153(1):126-38
pubmed: 23540694
Sci Transl Med. 2018 Jul 4;10(448):
pubmed: 29973404
Nat Commun. 2018 Mar 16;9(1):1111
pubmed: 29549260
PLoS Pathog. 2016 Aug 25;12(8):e1005815
pubmed: 27560183
Cell Host Microbe. 2014 Sep 10;16(3):304-13
pubmed: 25211073
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
Immunol Rev. 2017 Jan;275(1):145-160
pubmed: 28133802
J Virol. 2013 Feb;87(3):1554-68
pubmed: 23175357
Curr Opin HIV AIDS. 2019 Jul;14(4):286-293
pubmed: 30994504
Nat Commun. 2017 Mar 28;8:14954
pubmed: 28348411
Science. 2019 Dec 6;366(6470):
pubmed: 31806786
Protein Eng Des Sel. 2010 Apr;23(4):155-9
pubmed: 20130105
J Chem Theory Comput. 2016 Dec 13;12(12):6201-6212
pubmed: 27766851
Cell. 2016 Apr 7;165(2):449-63
pubmed: 26949186
Science. 2015 Jul 10;349(6244):aac4223
pubmed: 26089353
Cell. 2020 Jan 9;180(1):92-106.e11
pubmed: 31866068
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
PLoS Pathog. 2013;9(5):e1003342
pubmed: 23658524
Retrovirology. 2018 Sep 5;15(1):61
pubmed: 30185183
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W569-75
pubmed: 20462859
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298420
Cell. 2014 Jul 31;158(3):481-91
pubmed: 25065977
Nat Commun. 2018 Mar 28;9(1):1251
pubmed: 29593217
Cell Host Microbe. 2018 Jun 13;23(6):759-765.e6
pubmed: 29861171
AIDS. 2014 Jan 14;28(2):163-9
pubmed: 24361678
Biochemistry. 2016 Aug 30;55(34):4748-63
pubmed: 27490953
Nat Protoc. 2006;1(2):755-68
pubmed: 17406305
J Immunol. 2014 Feb 1;192(3):1100-1106
pubmed: 24391217
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
Immunity. 2016 Sep 20;45(3):483-496
pubmed: 27617678
Immunity. 2018 May 15;48(5):855-871
pubmed: 29768174
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):E3268-77
pubmed: 23115339
Cell Host Microbe. 2016 Mar 9;19(3):292-303
pubmed: 26922989
Cell. 2015 Apr 23;161(3):470-485
pubmed: 25865483
Science. 2019 Dec 6;366(6470):
pubmed: 31672916
Immunity. 2018 Dec 18;49(6):1162-1174.e8
pubmed: 30552024
Cell Rep. 2018 Aug 21;24(8):1958-1966.e5
pubmed: 30134158
Cell Host Microbe. 2020 Apr 8;27(4):531-543.e6
pubmed: 32130953
Cell. 2016 Sep 8;166(6):1445-1458.e12
pubmed: 27610569
Nature. 2011 Sep 22;477(7365):466-70
pubmed: 21849977
J Virol. 2010 Feb;84(3):1631-6
pubmed: 19923174
J Virol. 2009 Sep;83(17):8925-37
pubmed: 19553335
Nature. 2013 Apr 25;496(7446):469-76
pubmed: 23552890
Cell. 2016 Jun 30;166(1):77-87
pubmed: 27345369
PLoS Pathog. 2013;9(11):e1003754
pubmed: 24278016
Virology. 2006 Sep 30;353(2):268-82
pubmed: 17039602
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233

Auteurs

Olivia Swanson (O)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA.

Brianna Rhodes (B)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA.

Avivah Wang (A)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA.

Shi-Mao Xia (SM)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA.

Robert Parks (R)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA.

Haiyan Chen (H)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA.

Aja Sanzone (A)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA.

Melissa Cooper (M)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA.

Mark K Louder (MK)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.

Bob C Lin (BC)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.

Nicole A Doria-Rose (NA)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.

Mattia Bonsignori (M)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA; Department of Medicine, Duke University, Durham, NC 27610, USA.

Kevin O Saunders (KO)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA; Department of Surgery, Duke University, Durham, NC 27610, USA.

Kevin Wiehe (K)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA; Department of Medicine, Duke University, Durham, NC 27610, USA.

Barton F Haynes (BF)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA; Department of Medicine, Duke University, Durham, NC 27610, USA; Department of Immunology, Duke University, Durham, NC 27610, USA.

Mihai L Azoitei (ML)

Duke Human Vaccine Institute, Duke University, Durham, NC 27610, USA; Department of Medicine, Duke University, Durham, NC 27610, USA. Electronic address: mihai.azoitei@duke.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH